近日,诺和诺德在西班牙马德里举行的2025年欧洲心脏病学会(ESC)年会上公布了STEER真实世界研究的最新数据。该研究基于患者真实用药经历,评估了Wegovy®(司美格鲁肽2.4 mg)对比替尔泊肽在超重或肥胖且已确诊心血管疾病但无糖尿病的患者中预防主要不良心血管事件(MACE)的有效性。 结果显示,在所有接受治疗的患者中,无论是否存在用药中断,相比替尔泊肽,司美格鲁肽可使心脏病发作、卒中及...
Source Link近日,诺和诺德在西班牙马德里举行的2025年欧洲心脏病学会(ESC)年会上公布了STEER真实世界研究的最新数据。该研究基于患者真实用药经历,评估了Wegovy®(司美格鲁肽2.4 mg)对比替尔泊肽在超重或肥胖且已确诊心血管疾病但无糖尿病的患者中预防主要不良心血管事件(MACE)的有效性。 结果显示,在所有接受治疗的患者中,无论是否存在用药中断,相比替尔泊肽,司美格鲁肽可使心脏病发作、卒中及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.